These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33964292)

  • 21. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
    Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
    Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.
    Andersen JT; Dalhus B; Viuff D; Ravn BT; Gunnarsen KS; Plumridge A; Bunting K; Antunes F; Williamson R; Athwal S; Allan E; Evans L; Bjørås M; Kjærulff S; Sleep D; Sandlie I; Cameron J
    J Biol Chem; 2014 May; 289(19):13492-502. PubMed ID: 24652290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
    Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.
    Andersen JT; Daba MB; Berntzen G; Michaelsen TE; Sandlie I
    J Biol Chem; 2010 Feb; 285(7):4826-36. PubMed ID: 20018855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetically Encoding Albumin Binding into Chemotherapeutic-loaded Polypeptide Nanoparticles Enhances Their Antitumor Efficacy.
    Yousefpour P; McDaniel JR; Prasad V; Ahn L; Li X; Subrahmanyan R; Weitzhandler I; Suter S; Chilkoti A
    Nano Lett; 2018 Dec; 18(12):7784-7793. PubMed ID: 30461287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
    Mandrup OA; Ong SC; Lykkemark S; Dinesen A; Rudnik-Jansen I; Dagnæs-Hansen NF; Andersen JT; Alvarez-Vallina L; Howard KA
    Commun Biol; 2021 Mar; 4(1):310. PubMed ID: 33686177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T; Fossati G; Nesbitt A
    BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments.
    Mi W; Wanjie S; Lo ST; Gan Z; Pickl-Herk B; Ober RJ; Ward ES
    J Immunol; 2008 Dec; 181(11):7550-61. PubMed ID: 19017944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo.
    Yu F; Gudmundsdotter L; Akal A; Gunneriusson E; Frejd F; Nygren PÅ
    MAbs; 2014; 6(6):1598-607. PubMed ID: 25484067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β.
    Ji SI; Park JH; You HG; Chi HJ; Bang YW; Cha SH
    Immunol Lett; 2019 Mar; 207():46-55. PubMed ID: 30684504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin.
    Nguyen A; Reyes AE; Zhang M; McDonald P; Wong WL; Damico LA; Dennis MS
    Protein Eng Des Sel; 2006 Jul; 19(7):291-7. PubMed ID: 16621915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
    Zhang J; Bodenko V; Larkina M; Bezverkhniaia E; Xu T; Liao Y; Abouzayed A; Plotnikov E; Tretyakova M; Yuldasheva F; Belousov MV; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    J Control Release; 2024 Jun; 370():468-478. PubMed ID: 38697314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.
    Meyer S; Nederend M; Jansen JH; Reiding KR; Jacobino SR; Meeldijk J; Bovenschen N; Wuhrer M; Valerius T; Ubink R; Boross P; Rouwendal G; Leusen JH
    MAbs; 2016; 8(1):87-98. PubMed ID: 26466856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.
    Stork R; Müller D; Kontermann RE
    Protein Eng Des Sel; 2007 Nov; 20(11):569-76. PubMed ID: 17982179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Purification and characterization of a long-acting ciliary neurotrophic factor via genetically fused with an albumin-binding domain.
    Xu L; Zhang C; Liu L; Zhang Y; Wang Q; Wang J; Liu Y; Su Z
    Protein Expr Purif; 2017 Nov; 139():14-20. PubMed ID: 28711730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
    Proetzel G; Roopenian DC
    Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding.
    Davé E; Adams R; Zaccheo O; Carrington B; Compson JE; Dugdale S; Airey M; Malcolm S; Hailu H; Wild G; Turner A; Heads J; Sarkar K; Ventom A; Marshall D; Jairaj M; Kopotsha T; Christodoulou L; Zamacona M; Lawson AD; Heywood S; Humphreys DP
    MAbs; 2016 Oct; 8(7):1319-1335. PubMed ID: 27532598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity.
    Lee JY; Park T; Hong E; Amatya R; Park KA; Park YH; Min KA; Jin M; Lee S; Hwang S; Roh GS; Shin MC
    Biomaterials; 2020 Oct; 257():120250. PubMed ID: 32736262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.